Booth Andrew reported option exercise involving 50,000 shares of AbCellera Biologics Inc. at $0.32 for $16.1k on Nov 13, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Chief Financial Officer
Chief Financial Officer
Filed Nov 16, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$16,080Shares × reported price
Shares traded
50,000Common Shares
Price per share
$0.32Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
541,400Direct
Trade date
Nov 13, 2026Option exercise
Filed
Nov 16, 2026, 11:14 AM ET3-day reporting delay
Accession
0001834411-26-000013Code M · Transaction 401729
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 13, 2026Option exercise50,000$0.00$0Trade 401731
Nov 13, 2026Gift50,000$0.00$0Trade 401730
3 transaction rows in this filing. Joint filers share the same rows.

ABCL price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
ABCL · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 23, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago 0%1w ago 0%1d ago 0%
Returns since7d30d90d180d1y

Footnotes in full

F1: This transaction represents a charitable donation of 50,000 common shares the reporting person donated on November 13, 2026. F2: The shares subject to such option vest and become exercisable annually in substantially equal installments over a four-year period, with the first tranche vested on 22-Aug-2020, subject to the Reporting Person's continuous service to the Issuer on each such date.